CliffBio
small molecule

DUETACT

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

Loss of exclusivityJune 2028latest FDA-listed patent expiry
CompanyTAKEDA PHARMACEUTICALS USA INC

Drug detail

Brand nameDUETACT
Active ingredientGLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE
Strength2MG;30MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2006
Marketing statusRX

Listed patents

PatentExpiresType
8071130June 2028product
7700128January 2027product

More from TAKEDA PHARMACEUTICALS USA INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DUETACT patent cliff — loss of exclusivity June 2028 | CliffBio